Immuron Limited
(NASDAQ: IMRN)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $2.02 | Change: -0.14 | %Change: -6.52% | Volume: 18,714 |
Open: | $ 2.09 | Volume: | 18,714 | |
---|---|---|---|---|
High: | $ 2.20 | Yield(%) | 0.00 | |
Low: | $ 1.96 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 12.31M | |
EPS ($) | n/a | Shares Out: | 5.70M |
% Price Change (last 4 weeks): | -6.04 |
---|---|
% Price Change (last 13 weeks): | -19.96 |
% Price Change (last 26 weeks): | 13.74 |
% Price Change (last 52 weeks): | 10.82 |
% Price Change (year to date): | 15.20 |
Return on Equity (%): | -17.57 |
---|---|
Return on Assets (%): | -16.05 |
Return on Invested Capital (%): | -31.51 |
Gross Profit Margin (%): | 72.54 |
---|---|
Net Profit Margin (%): | -209.81 |
Operating Profit Margin (%): | -332.49 |
|
|
50-day Moving Average: | $2.31 |
---|---|
200-day Moving Average: | $2.06 |
Avg. Daily Vol. (last 50 days): | 6,240 |
Avg. Daily Vol. (last 200 days): | 287,792 |
52-wk high: | $5.96 |
52-wk low: | $1.48 |
Bid: | $2.08 |
Ask: | $2.80 |
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
|
Immuron Limited
62 Lygon Street Level 3 Carlton VI 3053 Phone: 61.3.9824.5254 Fax: n/a http://www.immuron.com |
Earnings (1year) ($): | -0.45 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 2.29 |
Cash Flow ($): | -0.44 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 9.48 |
Price/Book (x): | 0.88 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 8.82 |
---|---|
Current Ratio (x): | 9.20 |
LT Debt/Equity (x): | 0.77 |
Total Debt/Equity (x): | 0.96 |